Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways
Background and purpose: Fengshi Gutong capsule (FSGTC), a traditional herbal formula, has been used clinically in China for the treatment of arthritis. However, the mechanism underlying the therapeutic effects of FSGTC on osteoarthritis (OA) has not been elucidated. The present study investigated th...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2018.00910/full |
id |
doaj-e8dcc9b8ec304bc6bcaca26f857e94c6 |
---|---|
record_format |
Article |
spelling |
doaj-e8dcc9b8ec304bc6bcaca26f857e94c62020-11-25T00:06:27ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122018-08-01910.3389/fphar.2018.00910336303Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt PathwaysYao-Xin Gao0Hao-Heng Yu1Chuan He2Ming Li3Dan-Dan Guo4Jun-Jiang Lian5Hai-Jie Yang6Mian Wang7Lei Wang8Zhi-Wei Feng9Bin-Feng Cheng10Bin-Feng Cheng11School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaHenan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaSchool of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, ChinaSchool of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, ChinaThe First Affiliated Hospital of Xinxiang Medical University, Xinxiang, ChinaBackground and purpose: Fengshi Gutong capsule (FSGTC), a traditional herbal formula, has been used clinically in China for the treatment of arthritis. However, the mechanism underlying the therapeutic effects of FSGTC on osteoarthritis (OA) has not been elucidated. The present study investigated the function and mechanisms of FSGTC in rat OA model and interleukin (IL)-1β-stimulated synovial cells.Materials and methods: Rat OA model was established by intra-articular injection containing 4% papain. IL-1β-induced SW982 cells were used as an OA cell model. Safranin-O-Fast green (S-O) and hematoxylin-eosin (HE) stainings were used to observe the changes in cartilage morphology. Enzyme-linked immunosorbent assay (ELISA) and real-time quantitative PCR (qPCR) detected the expression of inflammatory cytokines. In addition, molecular mechanisms were analyzed by Western blot in the OA cell model.Results: FSGTC treatment significantly relieved the degeneration of cartilage and reduced the contents of tumor necrosis factor-α (TNF-α) and IL-6 in the serum in papain-induced OA rats. FSGTC also reduced the protein and mRNA levels of IL-6 and IL-8 in IL-1β-stimulated SW982 cells. Moreover, it inhibited the phosphorylation levels of ERK (extracellular signal-related kinase), JNK (c-Jun N-terminal kinase), p38, Akt (protein kinase B), and c-Jun. It also decreased the extent of IκBα degradation and p65 protein translocation into the nucleus.Conclusion: The current data confirmed the protective effects of FSGTC in the rat and OA cell models. The results suggested that FSGTC reduced the production of inflammatory mediators via restraining the activation of mitogen-activated protein kinases (MAPK), nuclear factor kappa B (NF-κB), activator protein-1 (AP-1), and Akt.https://www.frontiersin.org/article/10.3389/fphar.2018.00910/fullFengshi Gutong capsuleosteoarthritisrat OA modelsynovial cellspathways |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yao-Xin Gao Hao-Heng Yu Chuan He Ming Li Dan-Dan Guo Jun-Jiang Lian Hai-Jie Yang Mian Wang Lei Wang Zhi-Wei Feng Bin-Feng Cheng Bin-Feng Cheng |
spellingShingle |
Yao-Xin Gao Hao-Heng Yu Chuan He Ming Li Dan-Dan Guo Jun-Jiang Lian Hai-Jie Yang Mian Wang Lei Wang Zhi-Wei Feng Bin-Feng Cheng Bin-Feng Cheng Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways Frontiers in Pharmacology Fengshi Gutong capsule osteoarthritis rat OA model synovial cells pathways |
author_facet |
Yao-Xin Gao Hao-Heng Yu Chuan He Ming Li Dan-Dan Guo Jun-Jiang Lian Hai-Jie Yang Mian Wang Lei Wang Zhi-Wei Feng Bin-Feng Cheng Bin-Feng Cheng |
author_sort |
Yao-Xin Gao |
title |
Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways |
title_short |
Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways |
title_full |
Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways |
title_fullStr |
Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways |
title_full_unstemmed |
Fengshi Gutong Capsule Attenuates Osteoarthritis by Inhibiting MAPK, NF-κB, AP-1, and Akt Pathways |
title_sort |
fengshi gutong capsule attenuates osteoarthritis by inhibiting mapk, nf-κb, ap-1, and akt pathways |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2018-08-01 |
description |
Background and purpose: Fengshi Gutong capsule (FSGTC), a traditional herbal formula, has been used clinically in China for the treatment of arthritis. However, the mechanism underlying the therapeutic effects of FSGTC on osteoarthritis (OA) has not been elucidated. The present study investigated the function and mechanisms of FSGTC in rat OA model and interleukin (IL)-1β-stimulated synovial cells.Materials and methods: Rat OA model was established by intra-articular injection containing 4% papain. IL-1β-induced SW982 cells were used as an OA cell model. Safranin-O-Fast green (S-O) and hematoxylin-eosin (HE) stainings were used to observe the changes in cartilage morphology. Enzyme-linked immunosorbent assay (ELISA) and real-time quantitative PCR (qPCR) detected the expression of inflammatory cytokines. In addition, molecular mechanisms were analyzed by Western blot in the OA cell model.Results: FSGTC treatment significantly relieved the degeneration of cartilage and reduced the contents of tumor necrosis factor-α (TNF-α) and IL-6 in the serum in papain-induced OA rats. FSGTC also reduced the protein and mRNA levels of IL-6 and IL-8 in IL-1β-stimulated SW982 cells. Moreover, it inhibited the phosphorylation levels of ERK (extracellular signal-related kinase), JNK (c-Jun N-terminal kinase), p38, Akt (protein kinase B), and c-Jun. It also decreased the extent of IκBα degradation and p65 protein translocation into the nucleus.Conclusion: The current data confirmed the protective effects of FSGTC in the rat and OA cell models. The results suggested that FSGTC reduced the production of inflammatory mediators via restraining the activation of mitogen-activated protein kinases (MAPK), nuclear factor kappa B (NF-κB), activator protein-1 (AP-1), and Akt. |
topic |
Fengshi Gutong capsule osteoarthritis rat OA model synovial cells pathways |
url |
https://www.frontiersin.org/article/10.3389/fphar.2018.00910/full |
work_keys_str_mv |
AT yaoxingao fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways AT haohengyu fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways AT chuanhe fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways AT mingli fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways AT dandanguo fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways AT junjianglian fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways AT haijieyang fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways AT mianwang fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways AT leiwang fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways AT zhiweifeng fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways AT binfengcheng fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways AT binfengcheng fengshigutongcapsuleattenuatesosteoarthritisbyinhibitingmapknfkbap1andaktpathways |
_version_ |
1725421939279790080 |